Using blood level measurement to gauge the targeting dose of Ketamine infusion in treatment refractory depression.

Using blood level measurement to gauge the targeting dose of Ketamine infusion in treatment refractory depression. - Single Low-Dose Ketamine Injection in Treating Major Depression

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023588

Enrollment

Registered

2016-12-31

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Single Low-Dose Ketamine Injection in Treating Major Depression

Interventions

Ketamine(0.8mg/kg)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Diagnosis of major depressive disorder. 2.Voluntary patients with signed informed consent proved by institutional review board (IRB) 3.Age>=20y/o<65 y/o

Exclusion criteria

Exclusion criteria: 1.Major medical conditions (e.g., head injury, epilepsy, severe renal and cancer). 2.Pregnancy 3.Use of CNS intoxicant (eq. cocaine, cannabis, opiates) within the previous 24 hours. 4.Symptoms of substance abuse/dependence(except nicotine dependence) within 6 months 5.Lifetime use of ketamine or phencyclidine (PCP) 6.Diagnosis of psychosis or bipolar disorder 7.current NMDA antagonist medication (eq. Amantadine, Rimantadine, Lamotrigine, Memantine, Dextromethorphan) 8.Actively trying to commit suicide even in a hospital setting 9.Current homicide risk

Design outcomes

Primary

Measure	Time frame
The higher dose of intravenous ketamine needed for major depression in Chinese population	—

Countries

Asia(except Japan)

Contacts

Public ContactMu-Hong Chen

Taipei Veterans General Hospital,Taiwan Psychiatry Department

kremer7119@gmail.com+886-2-28757027

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026